, February 10, 2023 –

Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary needle-free vaccine technology, the high-density microarray patch (HD-MAP).

The Phase I clinical trial will assess the safety, tolerability, and immunogenicity of an IIV4 candidate in approximately 150 healthy participants, aged 18 – 50 years inclusive, who have not received an influenza vaccine within the last six months and have received no vaccines of any kind for at least thirty days prior to participating in the study. The trial is being conducted in Australia at three of the University of the Sunshine Coast’s clinical research locations in Brisbane, Morayfield and Sippy Downs.

The vaccine being delivered by Vaxxas’ HD-MAP in the study is a commercially available IIV4 from an undisclosed, world leading biopharmaceutical and medical device company.

A common infectious disease, influenza is responsible for three to five million severe cases worldwide annually, along with up to 650,000 deaths per year.1

The specific strains of influenza virus targeted in any given seasonal IIV4 are established annually by regulatory health agencies and encompass two strains of influenza A and two strains of influenza B. By targeting four significant strains of the influenza virus, quadrivalent influenza vaccines are designed to offer broad immune coverage against the flu viruses expected to circulate across the globe for a given flu season.

Vaxxas Chief Executive Officer David L. Hoey says administration of a quadrivalent influenza vaccine via a needle-free platform like Vaxxas’ HD-MAP has the potential to increase vaccination coverage and uptake.

“Vaccine delivered via HD-MAP patch technology removes the need for needle and syringe, is easy to use, and can potentially be self-administered. It also has the potential to simplify distribution by removing or reducing the need for refrigeration,” says Hoey.

In contrast to current influenza vaccines given by needle and syringe which must be stored under refrigerated conditions, typically 2C – 8C to remain effective, Vaxxas has shown in clinical trials that an influenza vaccine administered via the HD-MAP2 can be kept at temperatures up to 40C for at least 12 months, without losing effectiveness. These thermostability benefits of a HD-MAP influenza vaccine have the potential to enable broader distribution, at a lower cost.

Hoey continued, “The potential benefits of Vaxxas’ needle-free vaccine platform, supported by clinical trials, are all factors that could improve access to, and acceptability of, current influenza vaccines. This will offer greater protection each season to communities in Australia, and around the globe.”

Researchers estimate that fear of needles affects up to 25 percent of adults,3 and may lead to 16 percent of people4 in developed countries, including Australia and the US, skipping routine and pandemic vaccinations.

“We are excited by the potential of our needle-free, seasonal flu patch development program. This clinical trial builds upon our compelling body of data from clinical and preclinical studies using flu vaccines,” Mr Hoey added.

In addition to this seasonal IIV4/HD-MAP Phase I clinical trial, Vaxxas is preparing for clinical evaluation of pandemic influenza vaccine under contract with the United States Biomedical Advanced Research and Development Authority (BARDA). In 2022, the company also initiated a Phase I clinical study of the first COVID-19 vaccine candidate delivered using its HD-MAP technology.

– ENDS –

Media Enquiries

Media Enquiries
Amy Miller WE Communication +61 431 072 422 amymi@we-worldwide.com

About Vaxxas

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious disease and oncology.

Vaxxas’ core technology was initially developed at The University of Queensland (UQ), and the company was established as a start-up in 2011 by UQ’s commercialisation company UniQuest. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Partners, Brandon BioCatalyst, and US-based HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Government’s Innovation Investment Fund (IIF) program. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies. Learn more at www.one-ventures.com and www.brandoncapital.vc.

About Vaxxas’ HD-MAP Technology

The Company’s proprietary HD-MAP technology platform utilises an ultra-high-density array of projections – invisible to the naked human eye – applied to the skin as a patch sitting inside a small applicator device. When applied to the skin, the patch delivers vaccine to the abundant immune cells immediately below the skin surface. This approach can enhance the efficiency and effectiveness of resulting immune responses of vaccines.

Vaxxas uses proprietary dry-coating technology to apply an active and stable vaccine onto the projections which offers the potential to eliminate the need for vaccine refrigeration during storage and transportation – reducing the resource and logistics burden of maintaining the refrigerated “cold chain”. Ease of use of the HD-MAP could enable simplified administration, potentially encompassing self-administration.

To create the quadrivalent influenza vaccine patch candidate, Vaxxas’ HD-MAP is coated with a commercially available inactivated quadrivalent influenza vaccine and integrated into a single-use applicator, ready-for-vaccination. All vaccine candidates applied to the Vaxxas HD-MAP are designed to be effective and easy-to-use, while meeting industrial-scale manufacturing and commercial logistics requirements.

In extensive laboratory testing published in PLoS Med, Vaxxas’ HD-MAP delivered vaccines have been shown to be stable and remain active when stored and transported at room temperature and demonstrate greater safety and protection, along with a potential for a lower dose, when compared to needle and syringe delivery of vaccine antigens, including influenza as well as measles/rubella and COVID-19 SARS-CoV-2 spike protein. Vaxxas has completed three human clinical studies with its HD-MAP involving more than 300 participants, demonstrating safety, and enhanced immune response of vaccine administration by HD-MAP.


Vaxxas’ HD-MAP delivered vaccines are under investigation and available only for investigational uses. They are not available anywhere in the world for sale or purchase. As such, Vaxxas makes no claim that the vaccines are reliable, durable, dependable, safe or effective, and makes no claim that it is superior to any other vaccine or vaccine delivery technology.

1 Influenza (seasonal), World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)

2 Forster, A. H., Witham, K., Depelsenaire, A. C. I., Veitch, M., Wells, J. W., Wheatley, A., Pryor, M., Lickliter, J. D., Francis, B., Rockman, S., Bodle, J., Treasure, P., Hickling, J., & Fernando, G. J. P. (2020). Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. PLoS medicine, 17(3), e1003024. https://doi.org/10.1371/journal.pmed.1003024

3 Vaccine Administration, Centres for Disease Control and Prevention. Available at: https://www.cdc.gov/vaccines/pubs/pinkbook/vac-admin.html

4 McLenon, J., & Rogers, M. A. M. (2019). The fear of needles: A systematic review and meta-analysis. Journal of advanced nursing, 75(1), 30–42. https://doi.org/10.1111/jan.13818